Get the Stockscreener App
0.7484
2.81%
-0.0216
After Hours:
.75
0.0016
+0.21%
Casi Pharmaceuticals Inc stock is traded at $0.7484, with a volume of 30,337.
It is down -2.81% in the last 24 hours and down -30.70% over the past month.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
See More
Previous Close:
$0.77
Open:
$0.74
24h Volume:
30,337
Relative Volume:
0.88
Market Cap:
$15.38M
Revenue:
$31.56M
Net Income/Loss:
$-46.89M
P/E Ratio:
-0.2468
EPS:
-3.0329
Net Cash Flow:
$-26.70M
1W Performance:
-21.22%
1M Performance:
-30.70%
6M Performance:
-58.65%
1Y Performance:
-70.54%
1-Day Range:
$0.74
$0.814
1-Week Range:
$0.74
$0.98
52-Week Range:
$0.74
$3.09
Casi Pharmaceuticals Inc Stock (CASI) Company Profile
Name
Casi Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare CASI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CASI
Casi Pharmaceuticals Inc
|
0.7484 | 15.82M | 31.56M | -46.89M | -26.70M | -3.0329 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Initiated | Mizuho | Buy |
| Oct-23-20 | Initiated | Oppenheimer | Outperform |
| Sep-22-16 | Initiated | Maxim Group | Buy |
| Oct-29-15 | Resumed | H.C. Wainwright | Buy |
| Jun-23-15 | Initiated | H.C. Wainwright | Buy |
View All
Casi Pharmaceuticals Inc Stock (CASI) Latest News
CASI Pharmaceuticals Secures China Drug Registration for Thiotepa Ahead of Planned Asset Disposal - TipRanks
Weekly Earnings: What is the long term forecast for CASI Pharmaceuticals Inc stockMarket Trend Review & Low Risk Entry Point Guides - baoquankhu1.vn
CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely Bullish - MSN
CASI Pharmaceuticals Fails to Renew FOLOTYN Import License in China, Halts Sales - TipRanks
CASI Pharmaceuticals (NASDAQ: CASI) denied renewal of China FOLOTYN license - Stock Titan
CASI Pharmaceuticals Appeals Nasdaq Delisting Determination - MSN
Short Covering: Whats the profit margin of CASI Pharmaceuticals IncJuly 2025 Big Picture & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Will CASI Pharmaceuticals Inc. stock benefit from AI adoption2025 Price Targets & Verified Technical Trade Signals - bollywoodhelpline.com
China approves CASI Pharmaceuticals’ CID-103 clinical trial for kidney rejection - Investing.com Nigeria
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection - Investing News Network
China approves CASI Pharmaceuticals’ CID-103 clinical trial for kidney rejection By Investing.com - Investing.com South Africa
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR) - ACCESS Newswire
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Setup Watch: What is the long term forecast for CASI Pharmaceuticals Inc stock2025 Analyst Calls & Smart Investment Allocation Tips - baoquankhu1.vn
Merger Talk: Why CASI Pharmaceuticals Inc. stock is seen as undervaluedDollar Strength & Risk Controlled Daily Plans - Bộ Nội Vụ
CASI Pharmaceuticals Closes Second Tranche of US$20 Million Convertible Note Financing - TipRanks
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia - Investing News Network
CASI Pharmaceuticals : Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia - marketscreener.com
How CASI Pharmaceuticals Inc. stock trades during market volatility2025 Macro Impact & Safe Swing Trade Setup Alerts - Улправда
CASI Share Price | CASI Pharmaceuticals, Inc. Stock Analysis & Recommendation - MarketsMojo
Why CASI Pharmaceuticals Inc. stock could rally in 2025Portfolio Risk Summary & Accurate Entry and Exit Point Alerts - Улправда
Can CASI Pharmaceuticals Inc. stock maintain operating marginsWeekly Stock Recap & Momentum Based Trading Ideas - Улправда
CASI Pharmaceuticals closes first US$5 million tranche of convertible note financing - MSN
Aug Sentiment: Why CASI Pharmaceuticals Inc. stock could rally in 2025Market Activity Summary & Stepwise Trade Signal Guides - Улправда
CASI Pharmaceuticals wins Nasdaq extension to meet listing rules - MSN
CASI Pharmaceuticals Closes First US$5 Million Tranche of Convertible Note Financing - TipRanks
CASI Pharmaceuticals (NASDAQ: CASI) issues US$5M 12% convertible note as first tranche - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
CASI Pharmaceuticals Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Casi Pharmaceuticals secures Nasdaq listing extension until February 2026 By Investing.com - Investing.com Nigeria
CASI Pharmaceuticals Wins Nasdaq Listing Extension to February 2026 - TipRanks
CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements - Investing News Network
CASI Pharmaceuticals stock surges after Nasdaq grants listing extension By Investing.com - Investing.com Nigeria
CASI Pharmaceuticals stock surges after Nasdaq grants listing extension - Investing.com
Casi Pharmaceuticals secures Nasdaq listing extension until February 2026 - Investing.com
CASI Pharmaceuticals gets extra time to stay on Nasdaq - Stock Titan
Published on: 2025-12-21 10:42:27 - Улправда
What margin trends mean for CASI Pharmaceuticals Inc. stockTake Profit & Smart Swing Trading Techniques - Улправда
Is CASI Pharmaceuticals Inc. stock a safe buy before earnings2025 Price Momentum & AI Powered Market Trend Analysis - bolumsonucanavari.com
Will CASI Pharmaceuticals Inc. stock benefit from infrastructure spendingEarnings Overview Report & Daily Market Momentum Tracking - DonanımHaber
What valuation multiples suggest for CASI Pharmaceuticals Inc. stock2025 Market WrapUp & Reliable Breakout Forecasts - DonanımHaber
Fed Watch: What analyst consensus says on CASI Pharmaceuticals Inc. stockRate Hike & Reliable Breakout Forecasts - Улправда
Aug PreEarnings: Is CASI Pharmaceuticals Inc stock a contrarian buyJuly 2025 Analyst Calls & Growth Focused Stock Pick Reports - moha.gov.vn
CASI Pharmaceuticals, Inc. announced that it expects to receive $20 million in funding from Emerging Technology Partners, LLC - marketscreener.com
Casi Pharmaceuticals Inc Stock (CASI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):